Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.190
-0.330-3.47%
Volume:135.37M
Turnover:1.24B
Market Cap:105.89B
PE:27.05
High:9.510
Open:9.510
Low:9.015
Close:9.520
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.02
T/O Rate:1.17%
Dividend:0.30
Dividend Rate:3.31%
EPS(LYR):0.340
ROE:20.90%
ROA:10.70%
PB:2.41
PE(LYR):27.05
PS:2.90

Loading ...

CSPC Pharmaceutical Group Stock Advances 8.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 02

Hong Kong Stocks Add 1.8% in Morning Trading

Dow Jones
·
Jul 02

Movement Alert|CSPC Pharmaceutical Rises 6.74% in Regular Trading, Pharma Sector Rally Combined with Core Pipeline Catalysts

Market Focus
·
Jul 02

Jingfeng Pharmaceutical to Change Its Stock Ticker to "Shiyao Jingfeng"

Stock News
·
Jul 01

CSPC Pharmaceutical Begins Lung Cancer Trial in China

MT Newswires Live
·
Jul 01

CSPC Pharmaceutical - Initiates Phase Iii Trial of Sys 6010 with Enlonstobart in China

THOMSON REUTERS
·
Jun 30

CSPC Pharmaceutical Group Stock Falls 2.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jun 30

Movement Alert|CSPC Pharmaceutical Falls 3.08% in Regular Trading, Pharmaceutical Sector Faces Broad Selling Pressure After Prior Session Surge

Market Focus
·
Jun 30

Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI

Dow Jones
·
Jun 29

CSPC Pharmaceutical Group Stock Rallies 6.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jun 29

CSPC PHARMA Shares Surge Over 10% in Morning Trading as Key Phase III Trial Commences in China

Deep News
·
Jun 29

HK Movers | Hang Seng up More Than 2% Intraday, Led by CSPC PHARMA, INNOVENT BIO and Baidu

Tiger Newspress
·
Jun 29

Movement Alert|CSPC Pharmaceutical Rises 3.29% in Regular Trading, Core ADC Pipeline SYS6010 Initiates Phase III Clinical Trial

Market Focus
·
Jun 29

CSPC Pharmaceutical Group (SEHK:1093) Wins Two China Drug Milestones As Valuation Looks About Right

Simply Wall St.
·
Jun 29

CSPC Pharma Begins Phase III Trial of SYS6010 Combo for Lung Cancer Treatment

MT Newswires Live
·
Jun 26

Trustee of CSPC PHARMA Acquires 4.4 Million Shares Under Incentive Scheme

Stock News
·
Jun 26

CSPC Pharma: Trustee Acquires 4.40 Million Shares for 2026 Restricted Share Award Scheme

Bulletin Express
·
Jun 26

CSPC PHARMA's Phase III Trial for Novel NSCLC Combination Therapy Launches in China

Stock News
·
Jun 26

CSPC Starts China Phase III Trial of Sys6010-enlonstobart Combo in Driver Gene-negative NSCLC

Reuters
·
Jun 26

CSPC Pharma Trustee Buys 5,950,000 Shares for Hk$39.6 Million Under 2026 Award Scheme

Reuters
·
Jun 26